Literature DB >> 27067235

Predictive Value of CEA for Survival in Stage I Rectal Cancer: a Population-Based Propensity Score-Matched Analysis.

Ignazio Tarantino1, Rene Warschkow2,3, Bruno M Schmied2, Ulrich Güller4,5, Markus Mieth1, Thomas Cerny4, Markus W Büchler1, Alexis Ulrich6.   

Abstract

BACKGROUND: The aim of the study was to assess whether preoperative carcinoembryonic antigen (CEA) level is an independent predictor of overall- and cancer-specific survival in stage I rectal cancer.
METHODS: Stage I rectal cancer patients were identified in the Surveillance, Epidemiology, and End Results database between 2004 and 2011. The impact of an elevated preoperative CEA level (C1-stage) compared with a normal CEA level (C0-stage) on overall and cancer-specific survival was assessed using risk-adjusted Cox proportional hazard regression models and propensity score methods.
RESULTS: Overall, 1932 stage I rectal cancer patients were included, of which 328 (17 %) patients had C1-stage. The 5-year overall and cancer-specific survival for patients with C0-stage were 85.7 % (95 % CI 83.2-88.2 %) and 94.7 % (95 % CI 93.1-96.3 %), versus 76.8 % (95 % CI 70.9-83.1 %) and 88.1 % (95 % CI 83.3-93.2 %) for patients with C1-stage (P < 0.001 and P = 0.001). The negative impact of C1-stage on overall and cancer-specific survival was confirmed by risk-adjusted Cox proportional hazard regression analysis (hazard ratio [HR] = 1.57, 95 % CI = 1.15-2.16, P = 0.007 and 2.04, 95 % CI = 1.25-3.33, P = 0.006), and after propensity score matching (overall survival [OS]: HR = 1.46, 95 % CI = 1.02-2.08, P = 0.044 and cancer-specific survival [CSS]: HR = 3.28, 95 % CI = 1.78-6.03, P < 0.001).
CONCLUSION: This is the first population-based investigation of a large cohort of exclusively stage I rectal cancer patients providing compelling evidence that elevated preoperative CEA level is a strong predictor of worse overall and cancer-specific survival.

Entities:  

Keywords:  CEA; Carcinoembryonic antigen; Rectal cancer

Mesh:

Substances:

Year:  2016        PMID: 27067235     DOI: 10.1007/s11605-016-3137-8

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  26 in total

Review 1.  Invited commentary: propensity scores.

Authors:  M M Joffe; P R Rosenbaum
Journal:  Am J Epidemiol       Date:  1999-08-15       Impact factor: 4.897

2.  Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients.

Authors:  L E Harrison; J G Guillem; P Paty; A M Cohen
Journal:  J Am Coll Surg       Date:  1997-07       Impact factor: 6.113

3.  Stage I rectal cancer: identification of high-risk patients.

Authors:  D Blumberg; P B Paty; A I Picon; J G Guillem; D S Klimstra; B D Minsky; S H Quan; A M Cohen
Journal:  J Am Coll Surg       Date:  1998-05       Impact factor: 6.113

4.  Oncologic outcomes of pathologic stage I lower rectal cancer with or without preoperative chemoradiotherapy: are they comparable?

Authors:  Jung Wook Huh; Chang Hyun Kim; Hyeong Rok Kim; Young Jin Kim
Journal:  Surgery       Date:  2011-08-27       Impact factor: 3.982

5.  Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer.

Authors:  H J Wanebo; B Rao; C M Pinsky; R G Hoffman; M Stearns; M K Schwartz; H F Oettgen
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

6.  The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer.

Authors:  C G Moertel; J R O'Fallon; V L Go; M J O'Connell; G S Thynne
Journal:  Cancer       Date:  1986-08-01       Impact factor: 6.860

7.  Building the infrastructure for nationwide cancer surveillance and control--a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States).

Authors:  Phyllis A Wingo; Patricia M Jamison; Robert A Hiatt; Hannah K Weir; Paul M Gargiullo; Mary Hutton; Nancy C Lee; H Irene Hall
Journal:  Cancer Causes Control       Date:  2003-03       Impact factor: 2.506

8.  Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer.

Authors:  Ryo Takagawa; Syoichi Fujii; Mitsuyoshi Ohta; Yasuhiko Nagano; Chikara Kunisaki; Shigeru Yamagishi; Shunichi Osada; Yasushi Ichikawa; Hiroshi Shimada
Journal:  Ann Surg Oncol       Date:  2008-10-10       Impact factor: 5.344

9.  Liver metastases with 10 human colon carcinoma cell lines in nude mice and association with carcinoembryonic antigen production.

Authors:  L M Tibbetts; C M Doremus; G N Tzanakakis; M P Vezeridis
Journal:  Cancer       Date:  1993-01-15       Impact factor: 6.860

10.  Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients.

Authors:  I Tarantino; R Warschkow; M Worni; K Merati-Kashani; D Köberle; B M Schmied; S A Müller; T Steffen; T Cerny; U Güller
Journal:  Br J Cancer       Date:  2012-06-26       Impact factor: 7.640

View more
  8 in total

Review 1.  Pre-treatment carcinoembryonic antigen and outcome of patients with rectal cancer receiving neo-adjuvant chemo-radiation and surgical resection: a systematic review and meta-analysis.

Authors:  Giuseppe Colloca; Antonella Venturino; Pasquale Vitucci
Journal:  Med Oncol       Date:  2017-09-07       Impact factor: 3.064

2.  Elevated CEA is associated with worse survival in recurrent rectal cancer.

Authors:  Won Kyung Cho; Doo Ho Choi; Hee Chul Park; Won Park; Jeong Il Yu; Young Suk Park; Joon Oh Park; Ho Yeong Lim; Won Ki Kang; Hee Cheol Kim; Yong Beom Cho; Seong Hyeon Yun; Woo Yong Lee
Journal:  Oncotarget       Date:  2017-11-18

3.  Combination of carcinoembryonic antigen with the American Joint Committee on Cancer TNM staging system in rectal cancer: a real-world and large population-based study.

Authors:  Qi Liu; Peng Lian; Dakui Luo; Sanjun Cai; Qingguo Li; Xinxiang Li
Journal:  Onco Targets Ther       Date:  2018-09-13       Impact factor: 4.147

4.  A model of multiple tumor marker for lymph node metastasis assessment in colorectal cancer: a retrospective study.

Authors:  Jiangping Fu; Mengjie Tu; Yin Zhang; Yan Zhang; Jiasi Wang; Zhaoping Zeng; Jie Li; Fanxin Zeng
Journal:  PeerJ       Date:  2022-04-11       Impact factor: 2.984

5.  E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer.

Authors:  Haibo Wang; Wenjing Yang; Qiong Qin; Xiaomei Yang; Ying Yang; Hua Liu; Wenxiu Lu; Siyu Gu; Xuedi Cao; Duiping Feng; Zhongtao Zhang; Junqi He
Journal:  Mol Cancer       Date:  2022-07-22       Impact factor: 41.444

6.  Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients.

Authors:  Shufang Ning; Wene Wei; Jilin Li; Bingbing Hou; Jianhong Zhong; Yuxuan Xie; Haizhou Liu; Xianwei Mo; Jiansi Chen; Litu Zhang
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

7.  MicroRNA-95-3p inhibits cell proliferation and metastasis in colorectal carcinoma by HDGF.

Authors:  Yong-Gang Hong; Zhi-Ping Huang; Qi-Zhi Liu; Ji-Fu E; Xian-Hua Gao; Cheng Xin; Wei Zhang; Pengpeng Li; Li-Qiang Hao
Journal:  Biomed J       Date:  2020-05-14       Impact factor: 4.910

8.  Correlation study between serum neuro-specific enolase and gastric and colorectal cancers.

Authors:  Hai Luo; Kexin Shen; Hongyan Sun; Ruiqi Li; Zeming Wang; Zhongshi Xie
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.